MP46-20 HIGH-RESOLUTION, 18F-FLUCICLOVINE PET-MRI FOR MAPPING PROSTATE CANCER PRIOR TO FOCAL HIGH-INTENSITY FOCUSED ULTRASOUND

You have accessJournal of UrologyProstate Cancer: Localized: Ablative Therapy (MP46)1 Sep 2021MP46-20 HIGH-RESOLUTION, 18F-FLUCICLOVINE PET-MRI FOR MAPPING PROSTATE CANCER PRIOR TO FOCAL HIGH-INTENSITY FOCUSED ULTRASOUND Timothy Daskivich, Michael Luu, Jenny Park, Alessandro D'Agnolo, Rola Saouaf, Debiao Li, Yaniv Raphael, Sardius Chen, Yibin Xie, Marcio Diniz, Christopher Nguyen, and Hyung Kim DaskivichTimothy Daskivich More articles by this author , LuuMichael Luu ParkJenny Park D'AgnoloAlessandro D'Agnolo SaouafRola Saouaf LiDebiao Li RaphaelYaniv Raphael ChenSardius Chen XieYibin Xie DinizMarcio Diniz NguyenChristopher Nguyen KimHyung View All Author Informationhttps://doi.org/10.1097/JU.0000000000002067.20AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Partial-gland high intensity focused ultrasound (HIFU) requires accurate localization cancer within the prostate. We conducted a pilot trial determine if novel high-resolution DWI MRI sequence (hrMRI) 18F-fluciclovine-PET-MRI could identify biopsy-proven cancers not seen on standard multiparametric (mpMRI). METHODS: Candidates for hemigland HIFU were prospectively enrolled (unilateral Gleason≥7, PSA<20, stage≤cT2c) underwent 18F-fluciclovine-PET-MRI, hrMRI mpMRI. MR/ultrasound-fusion+systematic mapping biopsy was performed, targeting lesions (PIRADS3+ or PET+) identified any imaging modality. Patients with unilateral high-grade disease partial-gland HIFU. The primary endpoint sensitivity modalities cancer. secondary control based 6-month-post-HIFU-MR/ultrasound-fusion biopsy. RESULTS: Of 20 men enrolled, 13 eligible post-HIFU analysis. showed trend toward improvement in detection over mpMRI alone. When positive test defined as that either (PIRADS 3-5) PET positive, 0.56 (95%CI,0.44–0.78) compared 0.41 (95%CI, 0.31–0.60) alone (p=0.056). For GG2+ cancers, 0.60 0.46–0.90) 0.55 0.42–0.83) (p=0.32). Five PIRADS3+ but mpM RI, which 2 GG1 cancers. Eleven mpMRI, 1 GG2 cancer, affected treatment template (Figure). One eleven subjects had residual 6-month CONCLUSIONS: High-resolution may help fully characterize tumor burden prior focal Source Funding: Institutional © 2021 American Urological Association Education Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e821-e822 Advertisement Copyright & Permissions© Inc.MetricsAuthor Information Expand Loading ...